285 top medical experts on Neuroleptic Malignant Syndrome across 42 countries and 28 U.S. states, including 125 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see antipsychotic agents) which are in turn associated with dopaminergic receptor blockade (see receptors, dopamine) in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; tremor; high fever; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Basal Ganglia Diseases (3,177), Neurotoxicity Syndromes (2,322).
  4. Clinical Trials ClinicalTrials.gov : at least 2
  5. Synonyms: Neuroleptic-Induced Neuroleptic Malignant Syndrome,  Neuroleptic Induced Neuroleptic-Malignant Syndrome


  

        

                    


    Computing Expert Listing ...

);